Condition
MIGS
Total Trials
4
Recruiting
0
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Active Not Recruiting2
Completed1
Enrolling By Invitation1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07073937Enrolling By Invitation
Three Year Outcomes of Combined Hydrus Microstent With iTrack Canaloplasty
NCT05062668Completed
Efficacy and Safety of iStent Inject and Inject W in the Management of Primary Open-angle Glaucoma
NCT06909058Not ApplicableActive Not Recruiting
Postoperative Restrictions for Patients Undergoing Minimally Invasive Gynecologic Procedures
NCT05035394Not ApplicableActive Not Recruiting
Swedish Microinvasive Glaucoma Surgery Study (SMIGS)
Showing all 4 trials